8-K: CVS Health Revises 2024 Guidance After Q1 Results Show Medicare Utilization Pressure

CVS Health lowered its full-year 2024 earnings and cash flow guidance due to higher than expected medical costs, particularly in its Medicare Advantage business, despite a revenue increase in the first quarter.

Summary

• CVS Health reported a 3.7% increase in total revenues to $88.4 billion for the first quarter of 2024 compared to the prior year.
• However, GAAP diluted earnings per share decreased to $0.88 from $1.65, and adjusted EPS fell to $1.31 from $2.20 year-over-year.
• The company revised its full-year 2024 GAAP diluted EPS guidance to at least $5.64 from at least $7.06 and adjusted EPS guidance to at least $7.00 from at least $8.30.
• Full-year 2024 cash flow from operations guidance was also revised down to at least $10.5 billion from at least $12.0 billion.
• The primary driver for the reduced guidance is increased medical utilization, particularly within the Medicare Advantage business.
• The Health Care Benefits segment saw a significant decrease in adjusted operating income, down 59.9%, due to higher Medicare utilization and the impact of lower Medicare Advantage star ratings.
• The Health Services segment experienced a 9.7% decrease in total revenues, primarily due to the loss of a large client and pharmacy client price improvements.
• The Pharmacy & Consumer Wellness segment saw a 2.9% increase in total revenues, driven by increased prescription volume.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant downward revision of earnings and cash flow guidance, driven by higher medical costs and utilization. While revenue increased, the profitability and future outlook are concerning.

Positives

• Total revenues increased by 3.7% year-over-year, reaching $88.4 billion.
• The Pharmacy & Consumer Wellness segment saw a 2.9% increase in total revenues, driven by increased prescription volume.
• Medical membership increased by 1.3 million members year-over-year, reaching 26.8 million.
• Cash flow from operations was $4.9 billion for the quarter.

Negatives

• GAAP diluted EPS decreased by $0.77 year-over-year, falling to $0.88.
• Adjusted EPS decreased by $0.89 year-over-year, falling to $1.31.
• The Health Care Benefits segment experienced a 59.9% decrease in adjusted operating income.
• The Health Services segment saw a 9.7% decrease in total revenues.
• The company significantly lowered its full-year 2024 earnings and cash flow guidance.
• The medical benefit ratio (MBR) increased to 90.4%, indicating higher healthcare costs.
• Pharmacy claims processed decreased by 21.2% due to the loss of a large client.

Risks

• Continued elevated medical cost trends, particularly in the Medicare business, are expected to persist throughout 2024.
• The loss of a large client in the Health Services segment is negatively impacting revenue.
• Pharmacy client price improvements are putting pressure on the Health Services segment's revenue.
• The company faces challenges related to its Medicare Advantage star ratings.
• Increased interest expense due to higher debt levels is impacting profitability.

Future Outlook

CVS Health has revised its full-year 2024 guidance downward, anticipating that the elevated medical cost trends observed in the first quarter will persist throughout the year. The company now expects GAAP diluted EPS of at least $5.64 and adjusted EPS of at least $7.00, with cash flow from operations of at least $10.5 billion.

Management Comments

• The current environment does not diminish our opportunities, enthusiasm, or the long-term earnings power of our company.
• We are confident we have a pathway to address our near-term Medicare Advantage challenges.
• We remain committed to our strategy and believe that we have the right assets in place to deliver value to our customers, members, patients, and shareholders.

Industry Context

The results reflect broader challenges in the healthcare industry, particularly with rising medical costs and utilization rates, especially in the Medicare Advantage sector. Competitors in the health insurance and pharmacy benefit management space are likely facing similar pressures, making this a key trend to watch.

Comparison to Industry Standards

• UnitedHealth Group, a major competitor in the health insurance space, has also reported increased medical costs, indicating a broader industry trend.
• Other pharmacy benefit managers like Express Scripts may be experiencing similar pressures on pricing and client retention.
• The increase in the medical benefit ratio is a key metric that will be closely watched by investors and compared to peers like Humana and Centene.
• CVS's revised guidance is a significant adjustment and will likely be compared to the performance and outlook of its major competitors in the coming quarters.

Stakeholder Impact

• Shareholders will be negatively impacted by the reduced earnings and cash flow guidance.
• Customers may see changes in their healthcare plans and costs.
• Employees may experience uncertainty due to the company's performance challenges.
• Suppliers may be affected by changes in the company's purchasing patterns.

Next Steps

• The company will hold a conference call to discuss the first quarter results.
• CVS Health will need to address the challenges in its Medicare Advantage business to improve future performance.
• The company will likely focus on cost management and operational efficiencies to mitigate the impact of higher medical costs.

Key Dates

Keywords

CVS Health, Medicare Advantage, Earnings, Guidance, Healthcare, Pharmacy, Medical Benefit Ratio, PBM, EPS, Revenue